Eli Lilly

Lilly’s triple-agonist drug cuts weight 21% in diabetes trial

Eli Lilly announced on Tuesday that its experimental drug retatrutide helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial, marking the largest weight reduction ever recorded…

Novo Nordisk CEO says drugmaker ‘overpromised and underdelivered’

Novo Nordisk CEO Mike Doustdar acknowledged on Tuesday that the Danish drugmaker has "overpromised and underdelivered," eroding investor trust, as the company scrambles to chart a path beyond its blockbuster weight-loss franchise ahead of looming patent cliffs.

Novo’s CagriSema tops Eli Lilly’s tirzepatide in new trial

Novo unveiled new clinical data on Monday showing its experimental obesity drug CagriSema delivered superior weight loss compared to a lower dose of Eli Lilly's tirzepatide, offering a rebound for the company after its next-generation treatment stumbled in a head-to-head…

Novo Nordisk shares slide after growth plan fails to impress investors

Novo Nordisk shares fell as much as 7% in Copenhagen on Monday after the Danish drugmaker's Capital Markets Day in London failed to convince investors it has a credible near-term plan to sustain growth beyond its blockbuster Wegovy and Ozempic…

Patients report permanent vision loss linked to GLP-1 weight-loss drugs

A growing wave of lawsuits is targeting the makers of blockbuster GLP-1 weight-loss drugs, with patients alleging that medications including Ozempic, Wegovy, and Mounjaro caused sudden and permanent vision loss. The litigation, consolidated into a federal multidistrict proceeding, centers on…

Novo Nordisk rebrands as ‘Novo’ amid downgrade and pipeline setbacks

Morgan Stanley downgraded Novo Nordisk to Underweight from Equal-weight on September 11, citing a subdued medium-term growth outlook and rising concerns over the approaching patent cliff for semaglutide, the active ingredient behind the blockbuster drugs Ozempic and Wegovy. The bank…

Deutsche Bank cuts Novo Nordisk to Sell after 70% slide

Deutsche Bank became the first major bank to issue an outright Sell rating on Novo Nordisk since the Danish drugmaker's shares collapsed roughly 70% from their 2025 peak, cutting its price target by 9% to 265 Danish crowns from 290…

FDA clears Roche, Eli Lilly blood test for Alzheimer’s

The U.S. Food and Drug Administration has cleared a blood test developed by Roche in collaboration with Eli Lilly that can help detect signs of Alzheimer's disease through a simple blood draw, potentially transforming how the condition is diagnosed across…

Novo Nordisk shares slide despite earnings beat on Wegovy pill miss

Novo Nordisk shares fell more than 6% on Tuesday after the Danish drugmaker released its second-quarter 2026 earnings a day ahead of schedule, with investors seizing on a narrow miss in oral Wegovy sales and a cautious full-year outlook despite…

Novo Nordisk CEO pledges bolt-on deals after pipeline setbacks sink shares

Novo Nordisk CEO Mike Doustdar on Wednesday pledged to accelerate research and pursue bolt-on acquisitions to rebuild the Danish drugmaker's pipeline, as investors expressed frustration over a string of clinical trial setbacks that have overshadowed an upgraded 2026 outlook.

Novo Nordisk beats Q2 forecasts, raises 2026 outlook

Novo Nordisk, the Danish maker of weight-loss drug Wegovy, reported second-quarter adjusted operating profit that exceeded analyst expectations on Tuesday and raised its full-year 2026 outlook for the second time this year, citing stronger-than-expected sales of its GLP-1 drugs for…

Lilly plans Q1 2027 FDA filing for obesity drug retatrutide

Eli Lilly announced Thursday that it will submit a Biologics License Application for its next-generation obesity drug retatrutide to the U.S. Food and Drug Administration in the first quarter of 2027, after reporting positive results from two additional Phase 3…

Novo Nordisk demands price cuts from suppliers amid margin squeeze

Novo Nordisk has written to its suppliers requesting price reductions as the Danish pharmaceutical giant grapples with mounting cost pressures in a rapidly changing weight-loss drug market, according to a report by MedWatch on Wednesday. The correspondence gave suppliers only…

Eli Lilly says Trump pricing policy will delay obesity drug launches in Europe

Eli Lilly said on Tuesday that the Trump administration's most-favored-nation pricing policy will affect its plans to launch its weight-loss pill in Europe and Britain, with the rollout now expected in the second half of 2026 or early 2027. The…